Comparable stake leader
Kenneth R. Melani
SEC ownership of Medicus Pharma Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001997296.
Disclosed value leader
VELOCITY FUND PARTNERS, LP
Comparable rows
24/42
Latest evidence
03 Jun 2026
- Public ticker
- MDCX, MDCXW on Nasdaq
- Parsed ownership sources
- 13D/G, 3/4/5, and 13F
- Largest SEC-reported holder
- Kenneth R. Melani
- Latest 13D/G holder
- Kenneth R. Melani
- Latest parsed ownership date
- 03 Jun 2026
- Issuer CIK
- 0001997296
- Issuer location
- W. Conshohocken, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Medicus Pharma Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Kenneth R. Melani
Disclosed value leader
VELOCITY FUND PARTNERS, LP
Comparable rows
24/42
Latest evidence
03 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 18%
18 rows are not safely comparable across share classes.
13D/G row: Kenneth R. Melani
Showing 1-8 of 42 holder rows.
Quick read
Kenneth R. Melani leads the comparable SEC ownership view at 18%.
24 of 42 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Kenneth R. Melani's linked filing trail.
Comparable ownership
Top 5
Kenneth R. Melani
18%
ARMISTICE CAPITAL, LLC
5%
Raza Bokhari
4.8%
John Jason Hathaway
4.5%
Ajay Raju
3.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 42 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Kenneth R. Melani |
13D/G
3/4/5
Melani Kenneth R. · 10%+ Owner
|
18%
|
$9,843,685
3,248,741 shares
|
-$227,250 | 30 Jun 2025 |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
5%
|
$2,835,244
935,724 shares
|
-$1,000,736 | 30 Jun 2025 |
| Raza Bokhari |
13D/G
3/4/5
Bokhari Raza · Chief Executive Officer, Director
|
4.8%
|
$2,375,437
1,218,173 shares
|
+$316,875 | 31 Dec 2025 |
| John Jason Hathaway |
13D/G
John Hathaway
|
4.5%
|
$2,426,885
800,952 shares
|
$0 | 30 Jun 2025 |
| Ajay Raju |
13D/G
3/4/5
Raju Ajay · Director
|
3.7%
|
$893,750
2,031,250 shares
|
+$13,750 | 31 Mar 2026 |
| James P. Quinlan |
3/4/5
Chief Financial Officer
|
0.5%
|
$903,404
274,147 shares
mixed-class rows
|
— | 13 Aug 2025 |
| Interchange Capital Partners, LLC |
13F
Company
|
3%
|
$6,182,160
1,661,871 shares
|
— | 31 Mar 2026 |
| Virtu Financial LLC |
13F
Company
|
0.13%
|
$34,000
74,045 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Medicus Pharma Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
VELOCITY FUND PARTNERS, LP
Net 12M change
$0
Latest report
03 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| VELOCITY FUND PARTNERS, LP | 10%+ Owner | $38,572,068 | Mixed | 20 May 2025 | ||
| James P. Quinlan | Chief Financial Officer | $903,404 | Mixed | 13 Aug 2025 | ||
| Raza Bokhari | Chief Executive Officer, Director | $747,500 | Mixed | 03 Jun 2026 | ||
| Edward J. Brennan | Chief Scientific Officer | $149,500 | Mixed | 03 Jun 2026 | ||
| Faisal Mehmud | Chief Medical Officer | $149,500 | Mixed | 03 Jun 2026 | ||
| Carolyn F. Bonner | President and CFO | $149,500 | Mixed | 03 Jun 2026 | ||
| Larry Kaiser | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| Robert J. Ciaruffoli | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| William L. Ashton | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| Barry Fishman | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| Sara R. May | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| Patrick J. Mahaffy | Director | $74,413 | Mixed | 03 Jun 2026 | ||
| Andrew A. Smith | Chief Operating Officer | $496 | Mixed | 03 Jun 2026 | ||
| Frank W. Lavelle | Director | Mixed | 31 Dec 2024 | |||
| Kenneth R. Melani | 10%+ Owner | Mixed | 31 Dec 2024 | |||
| Ajay Raju | Director | Mixed | 03 Jun 2026 | |||
| Cathy McMorris Rodgers | Director | Mixed | 03 Jun 2026 |
Recent insider transactions for Medicus Pharma Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Andrew A. Smith | MDCX | Stock Option (right to buy) | Award | 200,000 | 200,000 | 03 Jun 2026 | Direct | |||
| Cathy McMorris Rodgers | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Ajay Raju | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Faisal Mehmud | MDCX | Stock Option (right to buy) | Award | 250,000 | 250,000 | 03 Jun 2026 | Direct | |||
| Sara R. May | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Patrick J. Mahaffy | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Larry Kaiser | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Barry Fishman | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Robert J. Ciaruffoli | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Edward J. Brennan | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 03 Jun 2026 | Direct | |||
| Carolyn F. Bonner | MDCX | Stock Option (right to buy) | Award | 250,000 | 250,000 | 03 Jun 2026 | Direct | |||
| Raza Bokhari | MDCX | Stock Option (right to buy) | Award | 500,000 | 500,000 | 03 Jun 2026 | Direct | |||
| William L. Ashton | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Andrew A. Smith | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 30 Mar 2026 | Direct | |||
| Cathy McMorris Rodgers | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Ajay Raju | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Faisal Mehmud | MDCX | Stock Option (right to buy) | Award | 125,000 | 125,000 | 30 Mar 2026 | Direct | |||
| Sara R. May | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Patrick J. Mahaffy | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Larry Kaiser | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Barry Fishman | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Robert J. Ciaruffoli | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Edward J. Brennan | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Carolyn F. Bonner | MDCX | Stock Option (right to buy) | Award | 100,000 | 100,000 | 30 Mar 2026 | Direct | |||
| Raza Bokhari | MDCX | Stock Option (right to buy) | Award | 325,000 | 325,000 | 30 Mar 2026 | Direct | |||
| William L. Ashton | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Andrew A. Smith | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 16 Dec 2025 | Direct | |||
| Cathy McMorris Rodgers | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Ajay Raju | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Faisal Mehmud | MDCX | Stock Option (right to buy) | Award | 75,000 | 75,000 | 16 Dec 2025 | Direct | |||
| Sara R. May | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Patrick J. Mahaffy | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Larry Kaiser | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Barry Fishman | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Robert J. Ciaruffoli | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Edward J. Brennan | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 16 Dec 2025 | Direct | |||
| Carolyn F. Bonner | MDCX | Stock Option (right to buy) | Award | 75,000 | 75,000 | 16 Dec 2025 | Direct | |||
| Raza Bokhari | MDCX | Stock Option (right to buy) | Award | 125,000 | 125,000 | 16 Dec 2025 | Direct | |||
| William L. Ashton | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| James P. Quinlan | MDCX | Common Shares | Options Exercise | 7.87% | 20,000 | 274,147 | 13 Aug 2025 | Direct | ||
| James P. Quinlan | MDCX | Common Shares, no par value ("Common Shares") | Options Exercise | 96.8% | 125,000 | 254,147 | 13 Aug 2025 | Direct | ||
| James P. Quinlan | MDCX | Stock Option (right to buy) | Options Exercise | -100% | -145,000 | 0 | 13 Aug 2025 | Direct | ||
| Ajay Raju | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 22 Jul 2025 | Direct | |||
| James P. Quinlan | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 22 Jul 2025 | Direct | |||
| Faisal Mehmud | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 22 Jul 2025 | Direct | |||
| Sara R. May | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 22 Jul 2025 | Direct | |||
| Larry Kaiser | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 22 Jul 2025 | Direct | |||
| Barry Fishman | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 22 Jul 2025 | Direct | |||
| Robert J. Ciaruffoli | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 22 Jul 2025 | Direct | |||
| Edward J. Brennan | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 22 Jul 2025 | Direct |
* marks a reported price that did not pass the local price check.